Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on June 3, 2020. The registrant is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol BSGM. The report addresses a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-driven disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the issuance of U.S. Patent No. 10,645,017 by the U.S. Patent and Trademark Office. The patent is titled "Systems, Apparatus and Methods for Conveying Biomedical Signals between a Patient and Monitoring and Treatment Devices." This intellectual property is intended to broadly protect the Company's flagship product, the PURE EP(tm) System.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the general context of the patent issuance. The primary commentary focuses on the strategic importance of the patent to the PURE EP(tm) System.
Investor Verification Checklist
- Verify the correct registrant name is BioSig Technologies, Inc. (BSGM), not Streamex Corp.
- Confirm the validity and scope of U.S. Patent No. 10,645,017 via the USPTO database.
- Review the attached Press Release (Exhibit 99.1) for detailed technical specifications of the PURE EP(tm) System.
- Check subsequent filings for any financial impact or commercialization updates related to this patent.